Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has
progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day
by continuous IV infusion for 7 consecutive days using a portable infusion pump.
Hospitalization is not required. Stable or responding patients will receive additional
gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum
total of 8 infusions, or 2 cycles after complete remission has been documented.
This study seeks to define the role of gallium nitrate in a specific population of patients
who are expected to have received prior therapy. Preliminary clinical studies have
suggested substantial evidence of antitumor activity in patients with relapsed or refractory
non-Hodgkin's Lymphoma treated with gallium nitrate.
Low- or intermediate-grade NHL using the International Working Formulation, subtypes IWF
Using the Updated REAL/WHO Classification, the following pathologic subtypes are eligible:
- Small lymphocytic lymphoma
- Lymphoplasmacytic lymphoma/immunocytoma
- Follicular lymphoma
- Diffuse large B-cell lymphoma
- Peripheral T-cell lymphoma, not otherwise characterized
Progression of disease following treatment with standard chemotherapy
Bi-dimensionally measurable disease
Performance Status: ECOG < = 2
Patients with mantle cell lymphoma or mycosis fungoides are not eligible
Patients with known history of CNS metastasis are not eligible